✦ LIBER ✦

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

✍ Scribed by Yood, Marianne Ulcickas; Oliveria, Susan A.; Cziraky, Mark; Hirji, Ishan; Hamdan, Muhammad; Davis, Catherine

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib and nilotinib in first-line tr

✍ Jame Abraham 📂 Article 📅 2010 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 77 KB

Different immunoprofiles in patients wit

✍ Hayashi, Yoshiki; Nakamae, Hirohisa; Katayama, Takako; Nakane, Takahiko; Koh, Hi 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 337 KB

Cross-intolerance to imatinib, dasatinib

✍ Igor Novitzky-Basso; Charles Craddock 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Nilotinib as frontline and second-line t

✍ Peter Valent; Günther Gastl; Klaus Geissler; Richard Greil; Oliver Hantschel; Al 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 138 KB

PCN47 COMPARISON OF HEALTH CARE RESOURCE

✍ EQ Wu; V Bollu; A Guo; A Guerin; M Tsaneva; D Williams; JD Griffin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Dasatinib: From Treatment of Imatinib-Re

✍ Brian L. Abbott 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 319 KB